摘要
目的评估肝硬化患者抗肝纤维化的治疗效果。方法选择50例肝硬化患者为研究对象,依据治疗方式不同分为对照组(n=25)与观察组(n=25)。对照组采用常规治疗,观察组在对照组常规治疗基础上加用扶正化瘀胶囊抗肝纤维化治疗。对比两组治疗前后肝功能四项[总胆红素(TBiL)、白蛋白(ALB)、谷丙转氨酶(ALT)、谷草转氨酶(AST)]水平,血清壳多糖酶3样蛋白1(CHI3L1)水平,血清前白蛋白(PA)水平,肝纤维化四项[血清透明质酸(HA)、Ⅲ型前胶原N端肽(PⅢNP)、Ⅳ型胶原(CⅣ)、层粘连蛋白(LN)]水平,肝脏硬度,门静脉宽度,临床症状改善情况,抗肝纤维化治疗效果,并发症发生情况。结果治疗24周后,两组ALT、AST、ALB水平均较治疗前显著改善,观察组TBiL水平较治疗前改善,且观察组ALB水平高于对照组(P<0.05)。治疗24周后,两组血清HA水平、PⅢNP水平、CⅣ水平、LN水平、血清CHI3L1水平、肝脏硬度、门静脉宽度均较治疗前下降,且观察组均低于对照组(P<0.05)。治疗24周后,两组血清PA水平均上升,且观察组血清PA水平(191.27±13.07)mg/L高于对照组的(179.60±15.44)mg/L(P<0.05)。两组经治疗后疲乏、腹胀、食欲不振、肝区隐痛等临床症状均消失。观察组抗纤维化总有效率88%明显优于对照组的16%(P<0.05)。观察组并发症发生率4%低于对照组的24%(P<0.05)。结论肝硬化患者在常规治疗基础上经抗肝纤维化治疗后,肝功能恢复程度、抗肝纤维化总有效率、肝脏硬度及门静脉压力下降幅度比单纯常规治疗效果好,并发症发生风险低。
Objective To evaluate the therapeutic efficacy of anti-liver fibrosis treatment in patients with liver cirrhosis.Methods 50 patients with liver cirrhosis were selected as the research subjects.They were divided into a control group(n=25)and an observation group(n=25)according to different treatment method.The control group received conventional treatment,and the observation group received additional anti liver fibrosis therapy with Fuzheng Huayu capsules in addition to conventional treatment of the control group.Patients in both groups were compared in terms of four liver function parameters[total bilirubin(TBiL),albumin(ALB),alanine aminotransferase(ALT),aspartate aminotransferase(AST)],serum chitosanase 3-like protein 1(CHI3L1),serum prealbumin(PA),liver fibrosis parameters[serum hyaluronic acid(HA),N-terminal peptide of typeⅢprocollagen(PⅢNP),typeⅣcollagen(CⅣ),and laminin(LN)],liver hardness,portal vein width,improvement of clinical symptoms,effectiveness of anti liver fibrosis,and complications.Results After 24 weeks of treatment,the levels of ALT,AST and ALB in both groups were significantly improved compared with those before treatment,and the level of TBiL was improved compared with that before treatment.Moreover,the ALB level was higher than that in the control group(P<0.05).After 24 weeks of treatment,the levels of serum HA,PⅢNP,CⅣ,LN,serum CHI3L1,liver stiffness,and portal vein width in both groups decreased compared with those before treatment,and the observation group was lower than the control group(P<0.05).After 24 weeks of treatment,the serum PA levels in both groups increased.The serum PA level in the observation group(191.27±13.07)mg/L was higher than the control group's(179.60±15.44)mg/L(P<0.05).After treatment,the clinical symptoms such as fatigue,abdominal distension,loss of appetite and dull pain in the hepatic region disappeared in both groups.The total effective rate of anti-fibrosis in the observation group was 88%,which was significantly better than the control group's 16%(P<0.05).The incidence of complications in the observation group was 4%,which was lower than the control group's 24%(P<0.05).Conclusion Patients with cirrhosis who receive anti fibrotic treatment on the basis of conventional treatment have better liver function recovery,anti-fibrotic efficacy,liver hardness,and portal vein pressure reduction than those receiving conventional treatment alone,and the risk of complications is reduced.
作者
龙高云
郭稳稳
程昌盛
吴燕
林文东
赖辉强
黄吉荣
LONG Gao-yun;GUO Wen-wen;CHENG Chang-sheng(Department of Hepatology,Guidong People's Hospital,Wuzhou 543000,China)
出处
《中国现代药物应用》
2026年第3期1-6,共6页
Chinese Journal of Modern Drug Application
基金
外周血CD4^(+)/CD8^(+)水平与PD-1单抗治疗晚期肝癌的相关性研究(项目编号:贺科技2024026)。
关键词
肝硬化
抗肝纤维化
壳多糖酶3样蛋白1
肝纤维化
治疗效果
Liver cirrhosis
Anti-liver fibrosis
Chitosanase 3-like protein 1
Liver fibrosis
Therapeutic effect
